A Nature Medicine study reports that severe gut complications after CAR T therapy in multiple myeloma are linked to persistent CAR T cells accumulating in the digestive tract. The work ties a mechanistic driver—continued immune cell presence in the gut—to a clinically meaningful adverse-event phenotype. The findings reinforce the need to distinguish transient on-target activity from prolonged persistence in tissues when managing GI toxicities and optimizing patient selection. For translational teams, the study also highlights potential avenues for monitoring strategies that track spatial persistence rather than relying only on systemic biomarkers. Clinically, the report may influence how teams think about risk stratification for GI complications, especially in heavily pretreated populations where CAR T expansion and trafficking may behave differently. For the CAR T ecosystem, the message is clear: next-generation protocols and supportive-care regimens may need to address not just immune activation, but tissue residency over time.